weight loss and semaglutide Semaglutide and Tirzepatide for Weight
Description
The EMPA-REG OUTCOME trial in patients with T2DM at high cardiovascular risk showed that the addition of empagliflozin to standard therapy reduced the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 14% and all-cause mortality by 32% (87)
60-Day Money-Back Guarantee
Until recently, the most significant side effects of semaglutide noted were mostly gastrointestinal symptoms such as nausea, vomiting, and diarrhea due to the drugs mechanism of action of delayed gastric emptying
Migraines affect approximately 12% of the adult population, with weight status playing a documented role in migraine frequency and severity
2024;7:e2431997
